Overview

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of selected dose 1.2mg/kg BID dosage administered subcutaneously (SC) administered PCI-27483 to metastatic or locally advanced pancreatic cancer patients receiving concurrent therapy with intravenously administered gemcitabine for 12 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Pharmacyclics LLC.

Treatments:

Gemcitabine